Multiple Myeloma – Access & Reimbursement – Detailed, Expanded Analysis (US)
MARKET OUTLOOK
Successive label expansions in the multiple myeloma treatment landscape are driving significant commercial reward for some well-entrenched current therapies. With Celgene’s Revlimid and Janssen / Takeda Pharmaceutical’s Velcade as cornerstones, emerging therapies such as Bluebird Bio / Celgene’s bb2121 and GlaxoSmithKline's GSK2857916 are pursuing initial approvals for the treatment of multiple myeloma and can expect premium pricing. Further, as a result of expected label expansions of current therapies, multiple myeloma regimens will increasingly include high-priced therapies. Understanding the market access drivers that are important to payers and oncologists will be essential in maximizing these therapies’ uptake.
QUESTIONS ANSWERED
- What roles do key brands such as Darzalex and Empliciti play in the treatment of multiple myeloma in the United States, and in what treatment settings are they typically prescribed?
- How broadly do MCOs cover multiple myeloma agents on their formularies, particularly for the regimens that include both oral and IV agents? What kind of restrictions do they apply to control usage?
- Do payers believe that the efficacy of the various therapies justifies their cost, and which drug do they think performs the best on clinical and other attributes?
- What are physicians’ views on emerging therapies such as bb2121 and GSK2857916, as well as the subcutaneous formulation of Darzalex? How do clinicians expect their prescribing to change, and what factors, if any, will drive these changes?
GEOGRAPHY
United States
PRIMARY RESEARCH
Survey of 100 hematologist-oncologists in the United States Survey of 32 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs)
KEY DRUGS COVERED
Current therapies: Darzalex, Empliciti, Kyprolis, Ninlaro, Pomalyst, Revlimid, Velcade
Emerging therapies: bb2121, GSK2857916, subcutaneous Darzalex
CONTENT HIGHLIGHTS
- Reimbursement and contracting
- Access and prescribing
- Special topics
- Opportunities and challenges for emerging therapies.
PRODUCT DESCRIPTION
U.S. Access & Reimbursement provides in-depth insight on the impact of payer policy on prescribing behavior so that clients can build their market access strategy and optimize their brand positioning. This analysis of primary market research with physician specialists and U.S. payers helps clients stay up-to-date on restriction policies, gauge payer and prescriber attitudes toward specific therapies, identify opportunities where brands can capture patient share through market access, and maximize opportunities for emerging therapies by learning how previous brands gained favorable reimbursement or why they stumbled.
Table of contents
- Multiple Myeloma - Access & Reimbursement - Detailed, Expanded Analysis (US)
- Access & Reimbursement Multiple Myeloma US November 2019
Paul Wilcock, Ph.D., is a senior analyst on the Oncology team at Clarivate. He has authored content on gastroesophageal cancer, multiple myeloma, breast cancer, hepatocellular carcinoma, renal cell carcinoma, as well as the treatment of malignant melanoma and breast cancer with Keytruda/Opdivo and Ibrance, respectively. In addition, he has written multi-indication reports such as the Real World Brand Tracker Summary and an Immune Checkpoint Inhibitor Special Topics report and has published oncology market assessment articles in Nature Reviews Drug Discovery. Previously, Dr. Wilcock was a research funding manager at Cancer Research UK, where he developed a deep understanding of drug discovery, predominantly in the academic setting. He received his doctorate from the University of Manchester, where he used systems biology to explore the role of cell signaling and hypoxia in oral cancer.
Chris Lewis is a primary research manager at Clarivate. She is responsible for the coordination, content review, and content generation of U.S. Access & Reimbursement reports, including authoring select A&R reports on managed care trends. Before this position, Ms. Lewis was a senior analyst at HealthLeaders-InterStudy. She analyzed the managed care markets in California, New York, and Pennsylvania. She also launched and authored the Pharmacy Benefit Manager profile series. She received her bachelor’s degree from California State University in Sacramento.
Snigdha Gupta, Ph.D., is a principal analyst on the Oncology team at Clarivate. She has worked on multiple oncology indications, including non-small-cell lung cancer and multiple myeloma. She holds a Ph.D. in infectious diseases from the Indian Institute of Chemical Biology at Jadavpur University in Kolkata. She pursued a postdoctoral fellowship at the Mucosal Immunology Lab of the National Institute of Immunology in New Delhi and has been published in several peer-reviewed journals.